Overview

The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss

Status:
Unknown status
Trial end date:
2018-12-22
Target enrollment:
Participant gender:
Summary
In this clinical cohort study, the investigators are going to observe the efficacy of anti-coagulation and immune therapy in the treatment of recurrent pregnancy loss with a prospective randomized controlled trial.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai First Maternity and Infant Hospital
Treatments:
Antibodies
Anticoagulants
Aspirin
Calcium heparin
Dalteparin
Dydrogesterone
Heparin
Heparin, Low-Molecular-Weight
Immunoglobulins
Immunoglobulins, Intravenous
Prednisone